MedTrace Logo

Early Versus Late ECMO Therapy in COVID-19 Induced ARDS (ECMO-VID)

NCT04341285 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2021-06-09

No results posted yet for this study

Summary

Experimental intervention: Insertion of Extracorporal Membrane Oxygenation (ECMO) within 24 hours of referral to an Intensive Care Unit.

Control intervention: Insertion of Extracorporal Membrane Oxygenation (ECMO) as rescue therapy following failure of conventional therapy for ARDS. This conventional therapy will be standardized to reduce bias.

Duration of intervention per patient: varies, depending on severity of pulmonary compromise Follow-up per patient: Until hospital discharge Accompanying measures: Serum Samples and bronchoscopy samples of patients included into the trial for secondary analysis of inflammatory parameters and potential biomarkers

Conditions

Interventions

PROCEDURE

ECMO Implantation

Insertion of Extracorporal Membrane Oxygenation (ECMO) within 24 hours of referral to an Intensive Care Unit.

Sponsors & Collaborators

  • University Hospital Freiburg

    collaborator OTHER

  • RWTH Aachen University

    collaborator OTHER

  • University Hospital Muenster

    collaborator OTHER

  • University Hospital Tuebingen

    lead OTHER

Principal Investigators

  • Peter Rosenberger, Prof. · +4970712986622

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-01
Primary Completion
2022-04-01
Completion
2022-05-01

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04341285 on ClinicalTrials.gov